Biosynexus Incorporated

Biosynexus Incorporated

Biotechnology, 9298 Gaither Rd, Gaithersburg, Maryland, 20877, United States, 11-50 Employees

biosynexus.com

  • LinkedIn

Who is BIOSYNEXUS INCORPORATED

Biosynexus Incorporated is a biopharmaceutical company that is developing a monoclonal antibody, pagibaximab, to prevent staphylococcal sepsis in very low birth weight (VLBW) infants in t...

Read More

map
  • 9298 Gaither Rd, Gaithersburg, Maryland, 20877, United States Headquarters: 9298 Gaither Rd, Gaithersburg, Maryland, 20877, United States
  • 1999 Date Founded: 1999
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies
  • Irwin Scher CEO:   Irwin Scher

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from BIOSYNEXUS INCORPORATED

Biosynexus Incorporated Org Chart and Mapping

VP-Level
Employees

Lillian Yu

Corporate Administrator

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Biosynexus Incorporated

Answer: Biosynexus Incorporated's headquarters are located at 9298 Gaither Rd, Gaithersburg, Maryland, 20877, United States

Answer: Biosynexus Incorporated's official website is https://biosynexus.com

Answer: Biosynexus Incorporated's revenue is $1 Million to $5 Million

Answer: Biosynexus Incorporated's SIC: 2834

Answer: Biosynexus Incorporated's NAICS: 325412

Answer: Biosynexus Incorporated has 11-50 employees

Answer: Biosynexus Incorporated is in Biotechnology

Answer: Biosynexus Incorporated contact info: Phone number: Website: https://biosynexus.com

Answer: Biosynexus Incorporated is a biopharmaceutical company that is developing a monoclonal antibody, pagibaximab, to prevent staphylococcal sepsis in very low birth weight (VLBW) infants in the setting of the neonatal intensive care unit (NICU). The company has two additional product candidates: lysostaphin for the treatment of life threatening staphylococcal infections and nisin a topical cream for treating serious skin infections. Biosynexus' mission is bringing products to the market for the prevention and treatment of bacterial infections with emphasis on the prevention of staphylococcal infections in VLBW infants.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access